A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
NCT06932458
Recruiting
Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%). For many years, the management of patients with CS IIA/B seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: London Health Sciences Centre, London, Ontario
Conditions: Testicular Cancer
Register for Updates
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06171750
Recruiting
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy. The study will be conducted in three parts; in Part 1, participants with superficial lesions will receive ANK-101 as a single agent; in Part 2, participants with visceral... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: National Cancer Institute, Bethesda, Maryland +4 locations
Conditions: Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Register for Updates
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
NCT04833894
Recruiting
The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
07/16/2025
Locations: Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois +23 locations
Conditions: Generalized Myasthenia Gravis
Register for Updates
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
NCT04574960
Recruiting
Upper tract urothelial cancer (UTUC) is cancer in the lining of the kidney or ureter (the tube that drains the kidney). This type of cancer is rare and as a result, there are only a few studies that have looked at it. Standard of care for UTUC would be surgery followed by chemotherapy (adjuvant chemotherapy). However, we know from studies that have looked at cancer of the lining of the bladder, which is a similar cancer in many ways, that treating people with chemotherapy before surgery (neoadj... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: The Ottawa Hospital, Ottawa, Ontario +1 locations
Conditions: Bladder Cancer, Bladder Urothelial Carcinoma
Register for Updates
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767
Recruiting
Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to destroy cancer cells or stop them from growing. After surger... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104), Los Angeles, California +73 locations
Conditions: Bladder Cancer
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220
Recruiting
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Site 36, La Jolla, California +143 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Evaluation of A Clinical Diagnostic Test for CRDS
NCT06188689
Recruiting
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Gender:
ALL
Ages:
All
Trial Updated:
07/16/2025
Locations: University of California, San Francisco, California +12 locations
Conditions: Calcium Release Deficiency Syndrome (CRDS)
Register for Updates
Enhancing Preschool Children's Attention and Behaviour: Parent-Focused Program
NCT07083037
Recruiting
This study aims to evaluate the feasibility and efficacy of the Building Regulation in Dual Generations (BRIDGE) program for caregivers with significant mental health concerns and preschool and young children (3-7 years old) with elevated attention and/or behavior problems. The BRIDGE program focuses on supporting parental psychological distress and improving young children's self-regulation (SR), thereby reducing their attention and behavior problems (Bridgett et al., 2015; Brikell et al., 2015... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: University of Manitoba - Department of Psychology, Winnipeg, Manitoba +1 locations
Conditions: Maternal Depression, Self-Regulation, Emotion, Child Mental Disorder, Child Development, Attention Problems, Behaviour Problems, Parental Stress
Register for Updates
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
NCT07082725
Recruiting
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease
Gender:
ALL
Ages:
4 years and above
Trial Updated:
07/16/2025
Locations: Children's Hospital and Research Center at Oakland, Oakland, California +26 locations
Conditions: Niemann-Pick Type C Disease
Register for Updates
Low INR to Minimize Bleeding With Mechanical Valves Trial
NCT03636295
Recruiting
This study evaluates the use of a lower INR target (1.5 to 2.5) in patients with a mechanical bileaflet heart valve in the aortic position. This study will inform physicians about whether a lower INR target will decrease the risk of bleeding or increase the risk of blood clot formation and stroke. These results have the potential to reduce the burden of bleeding in patients with a mechanical heart valve who require lifelong warfarin (Coumadin) treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Ziekenhuis Oost-Limburg, Genk, Limburg +25 locations
Conditions: Bleeding Post-mechanical Valve Replacement, Thromboembolism Post-mechanical Valve Replacement
Register for Updates
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose of ALN-HTT02.
Gender:
ALL
Ages:
Between 25 years and 70 years
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Edmonton, Not set +15 locations
Conditions: Huntington's Disease
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/15/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +81 locations
Conditions: Rheumatic Joint Disease
Register for Updates